Biotek-snakken — November 2025
-
Stifels take on Zyme https://x.com/BottomUpEquity/status/1990497466404208889/photo/1
-
De sidste fem år er der sket en voldsom konsolidering verden over inden for cannabis-branchen. Aktuelt har Stenocare netop købt en konkurrent, CannGros. I den forbindelse har Helge Larsen CEO Thomas Schnegelsberg og CFO Peter Bugge Johansen i studiet til en snak om strategien og økonomien bag opkøbet. https://proinvestor.com/boards/129833
-
BioPortos delårsresultat for tredje kvartal 2025 – Fortsat fremdrift og fortsat øget NGAL-salgsvækst https://proinvestor.com/investornyt/1384614/bioportos-delarsresultat-for-tredje-kvartal-2025-fortsat-fremdrift-og-fortsat-oget-ngal-salgsvaekst
-
Bioporto bekræfter nedjustering og udskudt indsendelse til myndighederne i USA https://proinvestor.com/investornyt/1384629/bioporto-bekraefter-nedjustering-og-udskudt-indsendelse-til-myndighederne-i-usa
-
Ny videointerview: Pila Pharma sigter mod en lukrativ first mover advantage
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind